INTRODUCTION
Interpretation of laboratory results is based on the clinical history, the medical context and on comparison of the patient's own results against established decision thresholds or reference intervals. Every analytical measurement has some sources of variability, which can be ascribed to changes in the physiological status of the patient (e.g. age, presence or progression of disease, response to treatment) and also to three inherent sources of variation, namely, biological variation (BV), pre-analytical variation, analytical imprecision (Fraser 2012) .
BV describes the physiological random fluctuation around a homeostatic set point, which is a characteristic of all blood measurands (Fraser 2001a,b,c) . This variation occurs within each individual, and it is designated as the within-subject biological coefficient of variation (CV I ). Furthermore, homeostatic set points vary between individuals in a population, and this difference is termed the between-subject biological coefficient of variation (CV G ).
CV I and CV G are established by BV studies that can be performed on relatively small numbers of subject animals representative of the population of interest, using serial collections and analysing data by nested analysis of variance (nANOVA) or restricted maximum likelihood (REML) (Freeman et al. 2017) . However, there is no need for each laboratory to generate CV I and CV G , a distinct advantage compared to population-based reference intervals, which should either be generated de novo for the specific instrument and method or validated by an analyserspecific study before transference (Geffre et al. 2009) .
CV I and CV G for many species and measurands can be obtained from literature (Wiinberg et al. 2007 , Ruaux et al. 2012 , Walton 2012 , Bourges-Abella et al. 2015 or databases available on the vetbiologicalvariation.org website (2015) . When data from different studies are available, CV I and CV G can be selected from the most suitable study and the most similar to the current clinical situation. If information is available, factors to consider include: type of sample, analyser/method, characteristics of the study population (e.g. total numbers of individuals, age, breed), numbers of sample per individual, concentration of the measurand, type of disease, length of monitoring period and sampling intervals (Soletormos et al. 2005) . Studies on BV are generally derived from healthy individuals. Studies in human medicine suggest that in the majority of cases CV I are generally similar in health and chronic stable disease (Carmen et al. 2007 , Fraser 2012 , although other studies have highlighted possible differences (Ruaux et al. 2015) . Until we have defined criteria on how to characterise chronic disease in veterinary patients, we believe it is reasonable to apply the available data ubiquitously to healthy and diseased patients.
Pre-analytical variation refers to variation attributable to patient preparation and sample collection (Fraser 2001a,b,c) . It can be minimised through good training, laboratory practice and written standard operating procedures, and many guidelines are available in the literature (Fraser 2001a ,b,c, Flatland et al. 2012 ). The analytical imprecision or analytical coefficient of variation (CV A ) is a performance characteristic of the analyser/method used to analyse the sample. It is important when applying formulae of BV that the laboratory's own CV A is used, not the CV A of the laboratory that originally conducted the BV study (Fraser 2001a ,b,c, 2012 , Soletormos et al. 2005 . Each laboratory should estimate its CV A from replicate analyses or from quality control studies using either pooled patient samples or quality control materials, with concentrations at or near clinical decision limits of interest (Flatland et al. 2010) . Pooled patient samples are preferred (Freeman et al. 2017) as the matrix of quality control materials may be different from patient serum, or it may contain stabiliser, additives, etc. that may have an effect (Westgard et al. 2008) . Several levels of concentration are likely to be necessary, representing the clinical interest or decision limits for that measurand. The CV A can be represented by the "average" CV or by the CV determined at the level of concentration closest to the result of the patient being evaluated. Preferably, precision studies should be conducted within the same day (between days is also acceptable, but it will introduce further variation) and should include 20 replicates of the sample, with arithmetical mean (average), SD and CV generated (Westgard et al. 2008 , Carey 2014 .
It has been demonstrated that if CV A ≤ 0·5 CV I (the coefficient of individual variation), it contributes to less than 12% of the total variability (analytical variation does not significantly affect judgement of BV); this standard is known as "desirable imprecision" (Fraser 2001a,b,c) .
CLINICAL APPLICATIONS OF BV DATA
Assessment of whether population-based reference interval or the subject-based reference interval should be used for interpretation of laboratory results Population-based reference intervals provide guidelines about the values found in health and disease, and they remain the most commonly used interpretative aid in diagnosis and clinical decision-making. However, they cannot be universally applied in all clinical settings because they are dependent on the performance of each analyser. Nowadays, it is recognised that every laboratory should generate its own reference intervals or at least validate transferability of reference intervals obtained from other sources (e.g. literature, manufacturer, etc.).
The individuality of the analyte also significantly influences reference intervals.
The Index of Individuality (II) expresses the relationship between CV I and CV G . It is most commonly calculated using the inverted formula (Freeman et al. 2017) :
CV A contributes to the overall variation. When this "analytical noise" is excessive, it may mask physiological variations, thus interfering with patient data interpretation.
To calculate II, it is recommended that CV CV CV Cotlove et al. 1970 , Fraser et al. 1997 . If the imprecision of a method is greater than this desirable value, efforts should be made to improve it, and consultation with Technical Support or another quality assurance expert should be considered. The II is used to investigate if traditional population-based reference intervals or subject-based reference intervals should be used for interpretation of laboratory results. For measurands with a low II (e.g. canine glucose in Fig. 1A ), the distribution of values from a single individual will cover much of the entire distribution of the reference interval. In other words, the intra-individual variability is higher than the inter-individual variability (CV I > CV G ); hence, when individuals have values that are even slightly unusual results for them, there is a high probability of these values lying outside the population-based reference interval. In contrast, for measurands with a high II (e.g. ALT in Fig.  1B ), the dispersion of values for any individual will span only a small part of the reference interval (CV I < CV G ). Individuals may have values that are very unusual for them but still lie within the population-based reference interval. Many routinely clinical laboratory measurands show high individuality.
Using the above formula for II, the interpretation is as follows:
• II > 1·67: high degree of individuality; the use of populationbased reference intervals is of low utility, and the reference change value (RCV) is likely to help detect significant changes in serial results.
• II < 0·7: low levels of individuality; the use of a traditional population-based reference interval is generally useful. RCV can be used for monitoring of changes in serial results.
• II between 0·7 and 1·67: moderate individuality; the use of both population-based reference intervals and RCV may be helpful in diagnosis and for monitoring of changes in serial results.
When serial results are being evaluated, the use of subjectbased reference intervals is appropriate.
Examples:
(a) In a study on BV of feline biochemistry results (Baral et al. 2014) , alkaline phosphatase shows CV A = 4·64%, CV I = 12·45% and CV G = 33·72%. Is the use of a population-based reference interval appropriate? The II can be calculated using Equation (1) 
Interpretation:
II is >1·67, so the use of a population-based reference interval may not always be able to identify changes in results that may be highly unusual for a particular individual, and the RCV should be helpful.
(b) We need to measure the glucose concentration in a serum sample of a dog suspected to be diabetic. Data on BV obtained from the online database indicate that glucose has an intermediate II (CV I = 10·7%, CV G = 10%, CV A 3·8%) (Ruaux et al. 2012 ), but we know our analyser has a less-then-desirable precision (lab CV A = 18·4%). Is the use of a population-based reference interval appropriate in this case?
The II can be calculated using Equation ( 
The use of a population-based reference interval is appropriate for diagnosis. RCV can be used for monitoring of serial results for progression of disease or monitoring treatment. However, effort should be made to improve the precision of the analyser. Determination of the number of samples needed to estimate the homeostatic set point for a measurand within an individual and within a specified range and probability In most clinical settings, a single test result is considered a reasonable estimate of the patient's homeostatic set point. However, there are circumstances when replicate or repeat samples may be indicated to increase the confidence in the interpretation of results (e.g. values borderline the clinical decision limit or an unusual result in a healthy individual). To calculate how many samples are needed to ensure that our estimate of the patient's homeostatic set point is within a certain percentage of the true value with a stated probability, we can use the following equation (Fraser 2001a ,b,c, Westgard 2009 :
where Z is the number of standard deviations appropriate for the chosen probability, and D is the desired percentage of closeness to the homeostatic set point.
Examples:
(a) A poorly controlled diabetic cat is investigated for causes of insulin resistance. As part of the diagnostic work-up, blood IGF-I is measured, to screen for acromegaly, at 165 nM (reference interval 21 to 153 nM) (Berg et al. 2007 ). Repeat sampling is considered to increase the confidence in the estimation of the true homeostatic set point of the patient. The laboratory CV A is 2·2%. CV I is available from the online database (Strage et al. 2015) , and it is 7·4%. How many samples are required to estimate, with a 95% probability, that the measured value is within 10% of the true concentration?
The numbers of repeat samples required can be calculated from Equation (2) 
Interpretation:
Three samples are required to estimate the measured IGF-I value within 10% of the true homeostatic point with a probability of 95%. The optimal interval between repeated sampling has not been determined, but several days are considered reasonable, and the three sample results should be averaged.
(b) As part of the diagnostic work-up of a dog with suspected hypothyroidism, a total T4 has been run as a screening test, and a value of 12·5 nmol/L was found, close to the lower limit of the population-based reference interval (13 to 51 nmol/L). Repeat sampling is considered to increase the confidence in the estimation of the true homeostatic set point of the patient. The lab CV A is 3·7%. CV I is available from the online database (Jensen & Høier 1996) , and it is 16·7%. How many samples are required to estimate if the measured value is within 10% of the true concentration with a 95% probability?
The numbers of repeat samples required can be calculated from Equation (1) 
In this case, 11 repeat samples would be needed, which would not be practical. Lowering the probability (lowering of Z value) or widening the window of acceptability (increasing D) would decrease the number of samples required, although it is still unlikely to be satisfactory. More appropriately, in this circumstance, the clinical decision should be based on a combination of the Total T4 result, clinical presentation and further testing (e.g. TSH and FreeT4).
Interpretation of single and replicate measurements during screening or diagnosis Data on BV can be a valuable aid in the interpretation of results, particularly when a measured value lies close to a cut-off value or clinical decision-making concentration.
The dispersion index (DI) expresses the distribution of concentrations around a measured value due to random variation. DI can be determined within a given probability as a percentage by the equation (Westgard 2009 ):
where Z is the number of standard deviations appropriate for the chosen probability and depending on whether the measurand is likely to require interpretation when concentrations are either increasing or decreasing (one-sided or unidirectional change) or for both (two-sided or bidirectional change). Z factors for normal distributions are provided in Table 1 . The factor n A is the number of replicate measurements; n S is the number of patient samples or specimens. For most clinical situations, a single assay (n A = 1) and single patient sample (n S = 1) are used. 
A dispersion calculator is available on the Westward QC website (2009).
From Equation (4), given a cut-off or decision limit value, it is possible to easily derive the highest concentration below that cut-off value (or the lowest concentration above it) that justifies clinical action, with a chosen probability:
Highest below cut-off concentration cut-off concentration 
The DI may be used to assess if the analyte concentration is significant in relation to a decision-making or cut-off concentration.
If the cut-off value lies outside the dispersion index (Fig. 2,  blue lines) , the clinical decision can be made based on a single sample with a confidence relative to the adopted probability. If the cut-off concentration lies within the DI (Fig. 2, red lines) , a single result is too uncertain as a basis for decision-making (it exceeds the chosen probability), and the utility of replicate or repeat samples may be considered before taking clinical action.
Example:
A dog with dyspnoea is suspected of having mitral regurgitation. A point-of-care troponin-I (C-TnI) determination is reported to distinguish between cardiogenic and non-cardiogenic causes of dyspnoea in dogs (median C-TnI concentration = 1·74 ng/mL and 0·14 ng/mL, respectively) (Payne et al. 2011) . A study determined that CV I = 26·3% for C-Tn-I in dogs with mitral regurgitation (Ruaux et al. 2015) . The patient's c-Tn-I result is 2·84 ng/mL, and the laboratory CV A is 13%. Can we confirm mitral regurgitation with 99% probability? What would it be the lowest above cut-off concentration that would confirm cardiac disease with a 99% probability?
DI can be calculated from Equations 3 and 4: The result of 2·84 could represent a result as low as 0·91 or as high as 4·77 ng/mL.
The lowest above cut-off concentration that would support cardiac disease in this dog can be calculated by Equation (6) Adopting a 95% probability, the cut-off value lies outside the DI, and clinical decision can be made with the stated confidence. Adopting a 99% probability, the cut-off value lies within the DI, and a single result is too uncertain as a basis for decision-making (it exceeds the chosen probability) 
Interpretation:
The cut-off value falls within the DI; therefore, we cannot confirm cardiac disease with a 99% probability. A lower probability can be selected by changing the Z factor and may be appropriate for clinical decision purposes (some studies suggest 80% probability may be acceptable). Alternatively, repeat sampling may be considered if there is a high clinical suspicion of mitral valve regurgitation.
The lowest above cut-off concentration that would support cardiac disease with a 99% probability is 2·92 ng/mL. This illustrates the importance of knowing dispersion around a result when a cut-off limit is applied.
Interpretation of serial measurements during monitoring When considering serial results, for a change to be significant with a stated probability, the numerical difference must be greater than the inherent variation due to analytical and BV, which is termed the reference change value (RCV) and traditionally calculated in percentage terms (Fraser 2001a ,b,c, 2012 , Soletormos et al. 2005 :
Where Z is the appropriate number of standard deviations based on desired probability (Table 1) , and √2 reflects that we are assessing the change between two serial results. Given a first measurand test result, we can think of RCV as a concentration range, with an upper and a lower limit that can be easily calculated as:
RCV concentration limits = measurand concentration + or -(measurand concentration × RCV)
RCV can be used to evaluate changes in two serial results for monitoring progression of disease or effect of treatments. Changes are considered "real" (i.e. not just the result of physiological variation or measurement imprecision) if they are greater than the RCV concentration limits (or, in other words, if the second test result falls outside these limits).
Recently, attention has been drawn to concern that when the traditional RCV calculations are applied to more than two consecutive results, they will increase the probability of false positive results (if change results in increase) and false negative results (if change results in decrease), especially with a high total coefficient of variation (CVT = 30 to 40%) (Lund et al. 2015a,b) . To solve this problem, the authors developed a new model based on log-normal distributions of BV data, recommending the use of Reference Change Factors to calculate the upper and lower limits for significant changes in a sequence of results. These factors are not included in this article but are mentioned as this may become the standard for evaluations in the future.
Example:
A mixed-breed, 20 kg dog with heart murmur and suspected cardiac disease was presented with an initial Nt-proBNP = 800 pmolL. The CV I = 33·9% (Ruaux 2015) , and the laboratory CV A = 11·8%. Serial monitoring protocol was planned at 30, 60, 90, 120 and 150 days to assess for changes in the clinical state of the patient and resulted in Nt-proBNP values of 900, 1200, 1500, 1800 and 2700 pmol/L, respectively. Are these changes significant when compared to the initial result, accepting a 95% probability?
RCV is calculated from Equation (7) 
Interpretation:
At 30 and 60 days, the Nt-proBNP concentration was not significantly increased. On subsequent days, the results were >1472 pmol/L and were considered significant compared to initial result, with 95% probability.
CONCLUSIONS
This article illustrates the traditional applications of BV in the clinical setting for dogs and cats. The critical number of tests calculation provides a gauge to determine if a single result is sufficient or reliable in making clinical decisions or if additional investigation may be needed (e.g. replicate assays, additional testing, correlations with other findings).
The DI is helpful in the identification of the "grey zones" around clinical decision limit values, where additional testing may be needed for interpretation of results.
The use of RCV provides an additional objective way to evaluate changes in trends in results.
We would like to highlight that analytical imprecision is an important component of RCV and that the laboratory's own CV A should be used when applying formulae for analysis of BV.
It is possible to use a within-assay CV A or inter-assay CV A to estimate the analytical imprecision. We suggest the use of the intra-assay CV A to be in line with the traditional approach opted in human medicine and in BV studies. CV A obtained from BV studies will usually be smaller than that obtained from other sources as it is determined from paired measurements and in conditions that minimise variation (e.g. done on the same day, using the same reagents, same operator, etc.). CV A obtained over time may be a better estimate of the variation that occurs between serial evaluations of patient samples, but it will inevitably be higher. If CV A is >0·5 CV I , the analytical variation will have a less-than-desirable weight on determination of RCV, leading to a loss of sensitivity and to the potential risk of missing clinically important changes.
The calculations illustrated in this paper are not currently supplied by veterinary laboratories but have been long applied in the in the National Health Service hospital at the University of Dundee medical centre, with changes in serial results highlighted as "significant" (95% probability) or "highly significant" (99% probability).
